List of Xofigo drug patents

Xofigo is owned by Bayer Hlthcare.

Xofigo contains Radium Ra-223 Dichloride.

Xofigo has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Xofigo are:

  • US6635234

Xofigo was authorised for market use on 15 May, 2013.

Xofigo is available in solution;intravenous dosage forms.

Xofigo can be used as therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

The generics of Xofigo are possible to be released after 17 November, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234 BAYER HLTHCARE Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Nov, 2022

(2 months ago)

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

Market Authorisation Date: 15 May, 2013

Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic